Drug Retail▲
Matsukiyo Cocokara Net Profit Up 14.9% to 14.86 Billion Yen, Shareholder Benefits Expanded from End of September
Matsukiyo Cocokara & Company, Japan's largest drugstore chain, reported increased revenue and profit for the first quarter of fiscal year ending March 2027, with net profit rising 14.9% year-on-year to 14.86 billion yen. Sales increased 5.7% to 289.35 billion yen, and operating profit rose 8.5% to 21.49 billion yen. The progress rate against full-year forecasts was 25.1% for sales and 24.6% for operating profit, almost in line with plans. The Matsumotokiyoshi Group business, the main profit driver, posted sales of 183.89 billion yen and segment profit of 16.1 billion yen, achieving an operating margin of 8.76%, surpassing the 5.6% of the Cocokara Fine Group business. Additionally, from the record date of September 30, 2026, shareholder benefits will be expanded for shareholders who have continuously held 1,000 shares or more for at least three years, increasing the benefit value from 5,000 yen to 10,000 yen.
Drug Retail▲
Tycoon Group 2026 Interim Net Profit Surges 183%
Tycoon Group Holdings Limited reported a net profit of approximately HK$6.3 million for the six months ended 30 June 2026, a year-on-year increase of 182.6% and a turnaround from the net loss of approximately HK$7.7 million in the same period last year. Revenue for the period was approximately HK$496.1 million, a slight decrease of 2.7% from HK$510.1 million in 1H2025, despite challenges such as rising operational costs and shifts in consumer spending. The company attributed the revenue resilience to its strong business model and strategic adjustments, including optimizing its product mix in Southeast Asia, where distribution sales fell 45.2% to HK$23.6 million but gross profit margins improved in Singapore and Malaysia. The board resolved not to declare an interim dividend for 1H2026, and the company expects improved revenue in the second half of 2026 due to the traditional peak consumption season.
Drug Retail▼
Dajia Weikang's 2026 interim report shows net profit of 7.2565 million yuan
Dajia Weikang released its 2026 interim report. The company's total operating revenue was 2.702 billion yuan, down 0.25% from the same period last year, and net profit attributable to the parent company was 7.2565 million yuan. Net cash inflow from operating activities was 11.4727 million yuan, the asset-liability ratio was 74.42%, gross margin was 18.30%, ROE was 0.49%, and diluted earnings per share was 0.04 yuan. The company had 13,600 shareholders, and the top ten shareholders held 55.89% of the total share capital.
Drug Retail▲
Huaren Health's 2026 interim report shows net profit of 136 million yuan
Huaren Health released its 2026 interim report, with total operating revenue of 2.825 billion yuan and net profit attributable to the parent company of 136 million yuan. Net cash inflow from operating activities was 410 million yuan, down 22.95% from the same period last year. The company's asset-liability ratio was 60.25%, gross margin was 34.72%, ROE was 6.41%, and diluted earnings per share was 0.34 yuan. The number of shareholders was 29,100, and the top ten shareholders held 65.97% of the total share capital.
Drug Retail
Yifeng Pharmacy Chain reports 2026 interim net profit of 964 million yuan
Yifeng Pharmacy Chain has released its 2026 interim report. Total operating revenue was 12.13 billion yuan, and net profit attributable to the parent company was 964 million yuan. Net cash inflow from operating activities was 1.454 billion yuan, a decrease of 116 million yuan from the same period last year, down 7.40 percent year on year. The company's latest asset-liability ratio was 49.82 percent, gross margin was 40.30 percent, down 0.17 percentage points from the same period last year, and latest return on equity was 7.95 percent. Diluted earnings per share were 0.79 yuan, total asset turnover was 0.46 times, and inventory turnover was 1.66 times. The company had 22,800 shareholders, and the top ten shareholders held 746 million shares, accounting for 61.49 percent of total share capital.
Drug Retail▲
Dajia Weikang's first-half net profit attributable to parent was 7.26 million yuan, up 712.1% year on year
Dajia Weikang released its 2026 half-year report. First-half net profit attributable to the parent was 7.26 million yuan, up 712.1% year on year. Operating revenue was 2.702 billion yuan, down 0.2% year on year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 720,000 yuan in the same period last year to a profit of 8.47 million yuan. Net operating cash flow was 11.47 million yuan, up 107.4% year on year. Earnings per share were 0.04 yuan. In the second quarter, operating revenue was 1.32 billion yuan, down 6.5% year on year, and net profit attributable to the parent swung from a loss of 2.25 million yuan in the same period last year to a profit of 1.29 million yuan. As of the end of the second quarter, total assets were 6.33 billion yuan, down 0.1% from the end of the previous year, and net assets attributable to the parent were 1.495 billion yuan, up 0.5%. The company said in the half-year report that the pharmaceutical distribution industry continues to develop amid trends toward standardization, consolidation, and digitalization. The company will deepen the integrated operation of intelligent warehousing hardware and digital supply chain systems, transform into a comprehensive supply chain service provider, and continue to expand in specialty pharmacies and health management.
Drug Retail▼
Yixintang's 2026 interim report shows net profit of 257 million yuan
Yixintang released its 2026 interim report. Total operating revenue was 8.467 billion yuan, down 5.02% from the same period last year, and net profit attributable to the parent company was 257 million yuan. Net cash inflow from operating activities was 1.249 billion yuan, the asset-liability ratio was 50.30%, gross margin was 33.23%, and diluted earnings per share was 0.45 yuan. The number of shareholders was 39,500, and the top ten shareholders held 55.00% of total share capital.
Drug Retail▲
Yifeng Pharmacy Chain Plans Dividend of 0.3 Yuan Per Share, Totaling 363 Million Yuan
Yifeng Pharmacy Chain announced on August 27 that it plans to distribute a cash dividend of 0.3 yuan per share, before tax, to all shareholders, with an estimated total payout of 363 million yuan, accounting for 37.63% of net profit attributable to the parent company for the first half of 2026. In the first half of 2026, Yifeng Pharmacy Chain achieved revenue of 12.13 billion yuan and net profit attributable to the parent company of 964 million yuan.
Drug Retail▼
Jianzhijia's 2026 interim net profit was RMB 53.654 million, down 25.87% year-on-year
Jianzhijia released its 2026 interim report, with total operating revenue of RMB 4.183 billion, down 6.14% year-on-year, and net profit attributable to the parent of RMB 53.654 million, down 25.87% year-on-year. Net cash inflow from operating activities was RMB 595 million, the asset-liability ratio was 72.58%, the gross margin was 36.30%, and diluted earnings per share was RMB 0.35, down 25.53% year-on-year. The number of shareholders was 13,400, and the top ten shareholders held 56.52% of the total share capital.
Drug Retail▲
Huaren Health's first-half net profit attributable to parent was 136 million yuan, up 31.0% year on year
Huaren Health released its 2026 interim report. First-half net profit attributable to the parent was 136 million yuan, up 31.0% year on year. Operating revenue was 2.82 billion yuan, up 12.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 132 million yuan, up 31.0% year on year. Net operating cash flow was 410 million yuan, down 23.0% year on year. Earnings per share were 0.3398 yuan. In the second quarter, operating revenue was 1.40 billion yuan, up 13.5% year on year, and net profit attributable to the parent was 56.57 million yuan, up 33.0% year on year. As of the end of the second quarter, the company's total assets were 5.468 billion yuan, down 0.4% from the end of the previous year, and net assets attributable to the parent were 2.119 billion yuan, up 1.1% from the end of the previous year. The company said its main operating businesses did not experience major changes during the reporting period. Pharmaceutical retail, pharmaceutical marketing, and drug research and development and production continued to advance steadily, and overall operations maintained steady growth.
Drug Retail▲
Yifeng Pharmacy's first-half net profit attributable to parent reaches 964 million yuan, up 9.5% year on year
Yifeng Pharmacy released its 2026 interim report, showing first-half net profit attributable to the parent of 964 million yuan, up 9.5% year on year. Operating revenue was 12.13 billion yuan, up 3.5% year on year; non-GAAP net profit attributable to the parent was 952 million yuan, up 11.1% year on year; net operating cash flow was 1.454 billion yuan, down 7.4% year on year; earnings per share were 0.7949 yuan. In the second quarter, operating revenue was 6.04 billion yuan, up 5.8% year on year, and net profit attributable to the parent was 464 million yuan, up 7.8% year on year. As of the end of the second quarter, total assets were 25.829 billion yuan, down 5.9% from the end of the previous year, and net assets attributable to the parent were 12.118 billion yuan, up 4.2% from the end of the previous year. During the reporting period, the company opened 211 self-operated stores, acquired 11 stores, added 263 new franchise stores, and closed 77 stores, bringing the total number of stores to 15,239, including 4,576 franchise stores. The company said there had been no material change in its operating conditions, and that it would continue to focus on the pharmaceutical retail business while actively expanding into emerging areas such as chronic disease management and internet healthcare.
Drug Retail▲
Yifeng Pharmacy's first-half attributable net profit was approximately 964 million yuan, up 9.51% year on year
Yifeng Pharmacy released its 2026 semi-annual report, with first-half attributable net profit of approximately 964 million yuan, up 9.51% year on year. The company's first-half operating revenue was approximately 12.13 billion yuan, up 3.48% year on year. Yifeng Pharmacy is mainly engaged in the omni-channel retail business of Chinese and Western patent medicines, traditional Chinese medicine decoction pieces, medical devices, health foods and other products. The company said revenue growth was mainly driven by organic growth at existing stores and expansion of franchise distribution business, while net profit growth benefited from revenue growth and a decline in expense ratio brought by cost reduction and efficiency improvement.
Drug Retail▲
Yifeng Pharmacy Chain's net profit up 9.51% year on year in first half of 2026
Yifeng Pharmacy Chain released its semi-annual report for 2026, achieving operating revenue of 12.13 billion yuan, up 3.48% year on year. Net profit attributable to shareholders of the listed company was 964 million yuan, up 9.51% year on year. The company plans to distribute a cash dividend of 0.30 yuan per share, tax included, to all shareholders. Based on calculations, the company's second-quarter net profit was 464 million yuan, compared with 500 million yuan in the first quarter, a quarter-on-quarter decline of 7%.
Drug Retail▼
Jianzhijia first-half net profit attributable to parent 53.65 million yuan, down 25.9% year on year
Jianzhijia released its 2026 interim report. First-half net profit attributable to the parent was 53.65 million yuan, down 25.9% year on year. Operating revenue was 4.183 billion yuan, down 6.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 43.38 million yuan, down 33.4% year on year. Net operating cash flow was 595 million yuan, up 8.0% year on year. Earnings per share were 0.35 yuan. In the second quarter, operating revenue was 2.09 billion yuan, down 3.3% year on year. Net profit attributable to the parent was 17.7 million yuan, down 54.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 10.42 million yuan, down 69.5% year on year. As of the end of the second quarter, total assets were 9.251 billion yuan, down 5.2% from the end of the previous year. Net assets attributable to the parent were 2.538 billion yuan, down 5.1% from the end of the previous year. The company said performance was under pressure mainly due to policy, market and industry factors, but through optimizing the supply chain and product mix, overall gross margin rose 0.61 percentage points year on year, while a 3.48% reduction in period expenses still failed to offset the pressure from declining revenue. The company has slowed store expansion and is focusing on improving the operating efficiency of existing stores.
Drug Retail▲
Shanghai No.1 Pharmacy reports 86.60% year-on-year rise in net profit for 2026 interim results
Shanghai No.1 Pharmacy released its 2026 interim report, with total operating revenue of 982 million yuan and net profit attributable to the parent company of 26.17 million yuan, an increase of 12.15 million yuan compared with the same period last year, up 86.60% year on year. Net cash inflow from operating activities was 21.37 million yuan, ranking sixth among peer companies that have disclosed results. The company's asset-liability ratio was 40.47%, down 4.03 percentage points from the same period last year; gross margin was 15.28%, up 0.58 percentage points from the previous quarter; ROE was 2.34%, up 1.07 percentage points from the same period last year. Diluted earnings per share were 0.12 yuan, up 86.49% year on year. The number of shareholders was 20,500, and the top ten shareholders held 53.74% of total share capital.
Drug Retail▼
Shuyu Pingmin's 2026 interim report shows net profit down 28.90%
Shuyu Pingmin released its 2026 interim report. Total operating revenue was 5.314 billion yuan, and net profit attributable to the parent company was 25.776 million yuan, down 28.90% from the same period last year. Net cash inflow from operating activities was 43.701 million yuan, down 68.30% year-on-year. The company's asset-liability ratio was 76.80%, gross margin was 26.44%, ROE was 1.23%, and diluted earnings per share was 0.06 yuan. The number of shareholders was 16,500, and the shareholding ratio of the top ten shareholders was 74.76%.
Drug Retail▲
Yixintang Proposes Cash Dividend of 2 Yuan per 10 Shares, Totaling 115 Million Yuan
Yixintang announced on August 26 that it plans to distribute a cash dividend of 2 yuan per 10 shares, before tax, to all shareholders, with an estimated total payout of 115 million yuan, accounting for 44.71% of net profit attributable to the parent company in the first half of 2026. In the interim period of 2026, Yixintang achieved revenue of 8.467 billion yuan and net profit attributable to the parent company of 257 million yuan.
Drug Retail▼
Ain Holdings resolves to adopt countermeasures against Oasis share accumulation
Ain Holdings announced on the 25th that it has resolved to adopt a policy for responding to large-scale purchases and other actions, in response to the share accumulation by Hong Kong-based investment fund Oasis Management. Oasis's shareholding ratio has reached 22.24%, and the company points out that information necessary for shareholders to judge the purpose and details of the share acquisition has not been disclosed, and that if further accumulation proceeds, it could have a serious impact on medium- to long-term corporate value and shareholder interests. If a large-scale purchase by Oasis is carried out or is likely to be carried out, the company will activate countermeasures such as the free allotment of share subscription rights, but will hold a general shareholders' meeting to confirm shareholders' intentions before doing so. The policy will remain in effect until the conclusion of the first board of directors meeting held after the annual general shareholders' meeting scheduled to be held by the end of July 2027. The company says this measure is intended to request Oasis to provide information necessary for shareholder judgment, evaluate the proposal at the board of directors, conduct negotiations and discussions, and secure the time necessary for shareholders to judge the merits of the large-scale purchase.
Drug Retail▼
Yaoyigou's 2026 interim report shows net loss of 9.5268 million yuan, widening year-on-year
Yaoyigou released its 2026 interim report, with net profit attributable to the parent company at negative 9.5268 million yuan, a loss expansion of 278,400 yuan compared with the same period last year. The company's total operating revenue was 2.181 billion yuan, and net cash inflow from operating activities was 7.1471 million yuan. The latest asset-liability ratio was 59.30%, up 1.68 percentage points from the previous quarter and up 6.13 percentage points from the same period last year. The latest gross margin was 9.17%, down 0.98 percentage points from the previous quarter and down 1.65 percentage points from the same period last year. The latest ROE was negative 1.17%, down 0.26 percentage points from the same period last year. The company's diluted earnings per share was negative 0.10 yuan.
Drug Retail▼
Shuyu Pingmin first-half net profit 25.776 million yuan, down 28.9% year on year
Shuyu Pingmin disclosed its 2026 semi-annual report on August 26. In the first half, it achieved total operating revenue of 5.314 billion yuan, up 8.86% year on year, but net profit attributable to the parent company was 25.776 million yuan, down 28.90% year on year. Net profit after deducting non-recurring items was 24.7604 million yuan, down 21.51% year on year, and net cash flow from operating activities was 43.701 million yuan, a sharp year-on-year decline of 68.30%. The company's main business is pharmaceutical retail chain operations. During the reporting period, the weighted average return on equity was 1.26%, down 0.63 percentage points year on year. As of the first half of 2026, the company's goodwill reached 2.304 billion yuan, equivalent to 109.54% of net assets in the same period, and the largest shareholder Li Wenjie and the second-largest shareholder Qin Guangxia had pledged 39.3% and 50.84% of their respective shareholdings.
Drug Retail▼
Shuyu Minmin first-half net profit attributable to parent falls 28.9% year on year to 25.78 million yuan
Shuyu Minmin released its 2026 half-year report, with net profit attributable to the parent company of 25.78 million yuan, down 28.9% year on year. Operating revenue was 5.31 billion yuan, up 8.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 24.76 million yuan, down 21.5% year on year. Net operating cash flow was 43.7 million yuan, down 68.3% year on year. Second-quarter net profit attributable to the parent was 15.42 million yuan, up 45.1% year on year. The company said that amid structural adjustment in the industry, the number of stores has declined, and it has closed some low-efficiency stores while continuing to advance digital transformation to improve operational efficiency.
Drug Retail▲
Black Rock Coffee Bar raises 2026 adjusted EBITDA guidance to $34M-$35M and lifts new store target to at least 38
Black Rock Coffee Bar raised its full-year 2026 adjusted EBITDA guidance to a range of $34 million to $35 million, up from the prior $33.5 million to $34.5 million, and increased its new store opening target to at least 38 from 36. The company reported second-quarter total revenue of $63 million, store-level profit of $19 million, and consolidated adjusted EBITDA of $9.4 million, with store-level margins expanding 70 basis points to 30.2%. Same-store sales rose 4.2%, or 15.1% on a two-year basis, while transactions declined 2%, partly due to free drink redemptions from a loyalty platform transition. Management noted that July same-store transactions turned positive at 1.7% and that the company reached 200 locations system-wide after opening 10 new stores in the quarter. Full-year total revenue is now expected in the range of $255 million to $257 million, with same-store sales growth in the mid-single digits.
Drug Retail▲
Laobaixing Launches 2026 Restricted Stock Incentive Plan, Proposes Grant of 9.78 Million Shares
Laobaixing has unveiled its 2026 restricted stock incentive plan, proposing to grant 9.78 million restricted shares, representing approximately 1.29% of the company's total share capital of 759 million shares, at a grant price of 6.37 yuan per share. The incentive targets no more than 230 individuals, including directors, senior management, middle management, and core staff. In the first quarter of 2026, the company achieved revenue of 5.481 billion yuan and net profit attributable to the parent company of 264 million yuan.
Drug Retail▲
LBX Pharmacy Launches Equity Incentive Plan with High Net Profit Growth Targets for Next Two Years
LBX Pharmacy has disclosed a dual incentive plan consisting of restricted stock and an employee stock ownership plan, setting high growth targets requiring net profit in 2027 and 2028 to increase by no less than 75 percent and 100 percent respectively, based on the 2025 net profit. The company plans to grant a total of 14.337 million shares to over 340 incentive recipients, with vesting conditions tied to substantial net profit growth, corresponding to a net profit of 946 million yuan in 2027 and 1.081 billion yuan in 2028. At the same time, the company has launched a share buyback program of 40 million to 80 million yuan, with a repurchase price not exceeding 18.08 yuan per share, and the repurchased shares will be used for the employee stock ownership plan and equity incentives. Boosted by this news, LBX Pharmacy's share price hit the daily limit up on August 11, closing at 14.01 yuan per share, with a total market capitalization exceeding 10.6 billion yuan.
Drug Retail▲
LBX Pharmacy Plans to Buy Back Shares Worth 40 Million to 80 Million Yuan
LBX Pharmacy announced plans to repurchase shares through centralized bidding, with an expected buyback amount of 40 million to 80 million yuan. The maximum repurchase price is set at 18.08 yuan per share, translating to approximately 2.21 million to 4.42 million shares, or 0.29% to 0.58% of total share capital. In the first quarter of 2026, the company reported revenue of 5.481 billion yuan and net profit attributable to the parent of 264 million yuan.
Drug Retail▲
Huaren Health Plans Private Placement to Raise Up to 709 Million Yuan for Smart Manufacturing and Other Projects
Huaren Health has released its 2026 plan for a private placement of A-shares to specific investors. The company intends to issue shares to no more than 35 specific investors, with the total number of shares not exceeding 50 million. The total funds raised will not exceed 709 million yuan. The proceeds will be used for a smart manufacturing and sorting center project, a pharmaceutical research and development project, an information technology construction project, and to supplement working capital.
Drug Retail▲
LBX Pharmacy Chain plans to buy back shares for 40 million to 80 million yuan
LBX Pharmacy Chain announced plans to buy back shares for 40 million to 80 million yuan, to be used for an employee stock ownership plan. If the above purposes are not implemented within 36 months after the completion of the share buyback, or if the repurchased shares are not fully used for the above purposes, the unused portion will be cancelled after completing relevant procedures. The buyback price will not exceed 18.08 yuan per share.
Drug Retail▲
Laobaixing Launches Share Buyback and Dual Incentive Plans, Targeting High Net Profit Growth Over the Next Two Years
Laobaixing has rolled out a package including a share buyback, a 2026 restricted stock incentive plan, and an employee stock ownership plan. It intends to grant a total of 14.337 million shares to over 340 incentive recipients. Based on the stock price at the time of the draft announcement, the total market value of the granted shares exceeds 180 million yuan. The company has set targets using 2025 net profit as the base, requiring net profit growth rates of no less than 75 percent and 100 percent in 2027 and 2028 respectively. That means achieving net profit of 946 million yuan in 2027 and 1.081 billion yuan in 2028. Meanwhile, the company plans to use its own funds or self-raised funds to implement a share buyback through centralized bidding. The total buyback amount will range from 40 million yuan to 80 million yuan, with a buyback price not exceeding 18.08 yuan per share. The estimated number of shares to be repurchased is between 2.2123 million and 4.4247 million shares. The repurchased shares will be used for the employee stock ownership plan and equity incentives. The incentive recipients precisely cover mid-to-senior management and core teams, with a focus on talent in information and digital AI business areas, aligning with the company's digital and AI transformation strategy. A maximum 31-month vesting period and an additional 6-month lock-up period have been set to deeply align personal interests with the company's medium- and long-term development.
Drug Retail▼
Rosen Law Firm Reminds Black Rock Coffee Investors of August 17 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of Black Rock Coffee Bar, Inc. securities of the August 17, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that in the Registration Statement for the September 2025 IPO and during the Class Period from September 12, 2025 to May 12, 2026, defendants made materially false and misleading statements and failed to disclose that new store openings were cannibalizing existing revenue, the expansion strategy was overstated in avoiding sales transfer, and financial results were materially impacted. If you purchased Black Rock Coffee securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Investors with losses in excess of $100,000 are encouraged to secure counsel before the deadline.
Drug Retail▼
SBS Law Reminds BRCB Investors of Securities Fraud Lawsuit Deadline
Schall, Brown & Schwartz LLP reminds investors of a class action lawsuit against Black Rock Coffee Bar, Inc. for alleged securities fraud. The lawsuit claims the company made false and misleading statements about the impact of newly opened stores cannibalizing sales from existing locations, which harmed financial results. Shareholders who purchased BRCB shares between September 12, 2025 and May 12, 2026 have until August 17, 2026 to seek lead plaintiff appointment.
Drug Retail▼
Hagens Berman Investigates Black Rock Coffee Bar Over IPO Disclosures on Sales Cannibalization
National shareholder rights firm Hagens Berman is investigating claims in a pending securities class action against Black Rock Coffee Bar, Inc., alleging the company and its senior executives provided false and misleading information about its expansion strategy during its September 2025 IPO and subsequent months. The suit contends that Black Rock Coffee's IPO documents and financial reports touted a 'concentric circle' expansion model with limited sales transfer, while new store openings were actually shifting customer traffic and revenue away from existing high-volume locations. Management allegedly continued to project aggressive growth targets while withholding internal data showing that store density was creating a significant sales transfer headwind to same-store sales growth. By the time the lawsuit was filed on June 18, 2026, Black Rock Coffee shares had declined to $7.72, over 61% below the IPO price. Investors who purchased stock traceable to the September 2025 IPO through May 12, 2026 have until August 17, 2026 to seek lead plaintiff appointment.
Drug Retail▼
Pomerantz Law Firm Reminds Black Rock Coffee Bar Investors of Class Action Deadline
Pomerantz LLP reminds investors of a class action lawsuit against Black Rock Coffee Bar, Inc. concerning alleged securities fraud or unlawful business practices. Investors who purchased or acquired Black Rock securities during the class period have until August 17, 2026, to seek appointment as lead plaintiff. The complaint follows Black Rock's May 12, 2026, announcement of first-quarter 2026 financial results, which revealed a same-store growth rate of 5.2%, a four-point year-over-year decline from 9.2% in the prior-year quarter, and revenue of $55.45 million that missed consensus estimates. On this news, Black Rock's stock price fell $3.32 per share, or 30.26%, to close at $7.65 per share on May 13, 2026. The company had conducted its initial public offering on or around September 12, 2025, selling 14.71 million shares at $20.00 per share.
Drug Retail▼
Glancy Prongay Wolke & Rotter LLP Reminds Black Rock Coffee Bar Investors of August 17 Lead Plaintiff Deadline
Glancy Prongay Wolke & Rotter LLP reminds investors of the August 17, 2026 deadline to file a lead plaintiff motion in a securities fraud class action against Black Rock Coffee Bar, Inc. The lawsuit covers investors who purchased or acquired Black Rock Coffee securities between September 12, 2025 and May 12, 2026. The complaint alleges that the company made false and misleading statements and failed to disclose that new store openings were cannibalizing existing sales, that its expansion strategy was overstated in avoiding sales transfer, and that its financial results were materially impacted. On May 12, 2026, Black Rock Coffee reported first quarter 2026 same-store growth of 5.2%, a decline from 9.2% a year earlier, and revenue of $55.45 million that missed estimates, causing its stock to fall 30.3% to $7.65 per share on May 13, 2026. The stock has since traded as low as $7.23, a more than 63% decline from its $20 IPO price on September 12, 2025.
Drug Retail▼
Rosen Law Firm Reminds Black Rock Coffee Investors of August 17 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of Black Rock Coffee Bar, Inc. securities that the lead plaintiff deadline in a securities class action is August 17, 2026. The class action covers investors who acquired Class A common stock pursuant to the September 2025 IPO registration statement or purchased securities between September 12, 2025 and May 12, 2026. If you purchased Black Rock Coffee securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that the company made misleading statements and failed to disclose that new store openings were cannibalizing existing revenue, that its expansion strategy was overstated, and that financial results were materially impacted.
Drug Retail▼
Robbins LLP Reminds Black Rock Coffee Bar Investors of Lead Plaintiff Deadline
Robbins LLP reminds investors that a class action lawsuit has been filed against Black Rock Coffee Bar, Inc. on behalf of those who purchased or acquired securities in connection with the company's September 2025 IPO or between September 12, 2025 and May 12, 2026. The lawsuit alleges the company misled investors about its growth prospects, expansion strategy, and financial performance, including failing to disclose that new store openings were cannibalizing existing locations and causing sales transfer. On May 12, 2026, Black Rock Coffee reported first-quarter same-store sales growth of 5.2%, down from 9.2% a year earlier, and revenue of $55.45 million that missed estimates, leading to a 30.3% stock drop the next day. The deadline to seek lead plaintiff appointment is August 17, 2026.
Drug Retail▼
Black Rock Coffee Bar Investors May Seek Lead Plaintiff Role in Securities Class Action
The Gross Law Firm has issued a shareholder alert for Black Rock Coffee Bar, Inc., notifying investors who purchased shares during the class period that they may seek lead plaintiff appointment in a securities lawsuit. The class period covers those who acquired Class A common stock in the September 2025 IPO or purchased securities between September 12, 2025 and May 12, 2026. The complaint alleges that the company made false or misleading statements and failed to disclose that new store openings were cannibalizing existing revenue, that its expansion strategy overstated avoidance of sales transfer, and that financial results were materially impacted as a result. The deadline to seek lead plaintiff status is August 17, 2026, and there is no cost or obligation to participate.
Drug Retail▼
Bragar Eagel & Squire Reminds Black Rock Coffee Bar Investors of August 17 Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. reminds investors in Black Rock Coffee Bar, Inc. that they have until August 17, 2026 to seek appointment as lead plaintiff in a class action lawsuit. The suit, filed in the United States District Court for the Southern District of New York, covers purchasers of Class A common stock traceable to the company's September 2025 initial public offering and those who acquired securities between September 12, 2025 and May 12, 2026. The complaint alleges that the IPO sold 16,911,764 shares at $20.00 per share, generating net proceeds of approximately $306.5 million, and that on May 12, 2026, Black Rock reported first-quarter 2026 earnings per share of $0.02 and revenue of $55.5 million, both missing consensus estimates. Investors who suffered losses can contact the firm at investigations@bespc.com or (212) 355-4648.
Drug Retail▼
Black Rock Coffee Bar investors have until August 17, 2026 to join securities class action
Bernstein Liebhard LLP reminds Black Rock Coffee Bar, Inc. investors that the deadline to join a securities fraud class action lawsuit is August 17, 2026. The lawsuit covers those who purchased shares in the September 2025 IPO or acquired securities between September 12, 2025 and May 12, 2026. It alleges the company and certain senior officers made false and misleading statements about business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the firm to participate, with lead plaintiff motions due by the August deadline. Bernstein Liebhard has recovered over $3.5 billion for clients since 1993.
Drug Retail▼
Pomerantz Law Firm Reminds Black Rock Coffee Bar Investors of Class Action Deadline
Pomerantz LLP reminds investors of a class action lawsuit against Black Rock Coffee Bar, Inc. with a lead plaintiff deadline of August 17, 2026. The lawsuit concerns whether Black Rock and certain officers or directors engaged in securities fraud or other unlawful business practices. The company conducted its IPO on or around September 12, 2025, selling 14.71 million shares at $20.00 per share. On May 12, 2026, Black Rock reported first quarter 2026 results including a same store growth rate of 5.2%, down from 9.2% a year earlier, and revenue of $55.45 million that missed consensus estimates. Following the news, the stock fell $3.32 per share, or 30.26%, to close at $7.65 per share on May 13, 2026.
Drug Retail▲
Hong Kong Fund Oasis Raises Stake in Ain Holdings to 18.75%
Hong Kong investment fund Oasis Management has increased its stake in Ain Holdings, raising its holding ratio to 18.75%, according to a change report filed on the 28th. The previous report in June showed a stake of 17.74%. The reporting obligation date was July 21. The purpose of the holding remains pure investment, and the fund plans to acquire an additional stake exceeding 5% if certain conditions are met.